Home>Topics>Companies>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

  1. All
  2. Commentary
  3. Headlines
  1. Japanese health regulator approves Eylea label expansion

    Headlines

    Mon, 22 Sep 2014

    Welfare approves the use of Regeneron Pharmaceuticals ' (NASDAQ: REGN ) Eylea (aflibercept) injection ..... neovascularization (myopic CNV). Eylea is already approved for sale ..... vein occlusion (CRVO). Eylea is marketed in Japan by Bayer

  2. Regeneron Is Regenerating Growth In My Portfolio Once Again

    Headlines

    Sun, 21 Sep 2014

    up some gains. I ended up buying shares of Regeneron Pharmaceuticals , Inc . (NASDAQ: REGN ) because I wanted to buy back into the growth stock. Regeneron is a fully integrated biopharmaceutical company

  3. BTD tag for Eylea for diabetic retinopathy in DME

    Headlines

    Tue, 16 Sep 2014

    The FDA designates Regeneron Pharmaceuticals ' (NASDAQ: REGN ) Eylea ( aflibercept ) a Breakthough Therapy (BTD) for the ..... of more-intensive agency guidance and discussion. Eylea is currently approved for the treatment of wet age-related

  4. Sanofi: Riding The Growth Trend

    Headlines

    Mon, 8 Sep 2014

    analyze Sanofi's pipeline and its valuation. Positive Data from Sanofi and Regeneron Pharmaceutical's Cholesterol Drug Sanofi and Regeneron Pharmaceuticals (NASDAQ: REGN ) recently announced positive results from a Phase 3 ODYSSEY trial of Alirocumab

  5. There Is Further Upside Potential In Regeneron Pharmaceuticals

    Headlines

    Mon, 8 Sep 2014

    general, Regeneron Pharmaceuticals Inc . (NASDAQ: REGN ) is an exception ..... surprise. Regeneron 's EYLEA is on track ..... Recently, EYLEA also received ..... alirocumab. Regeneron and Sanofi ..... upside in Regeneron even as the

  6. Regeneron Reports Solid 2Q Eylea Sales, Continued Pipeline Progress; Maintaining Fair Value

    Commentary

    Tue, 5 Aug 2014

    Regeneron reported second-quarter results that ..... better than anticipated, with U.S. Eylea sales rebounding strongly after a sluggish ..... first-quarter results. Rest of world Eylea sales, as reported by partner Bayer ..... Despite higher SG&A costs related to Eylea 's commercialization and increased ..... hypercholesterolemia patients. Importantly, Regeneron also disclosed that in a prespecified

  7. A New Indication for Eylea and Positive Phase III Results for Alirocumab; Raising FVE

    Commentary

    Wed, 30 Jul 2014

    Regeneron has reported two meaningful pipeline ..... Food and Drug Administration approved Eylea on July 29 in diabetic macular edema ..... treating high cholesterol. While the Eylea news was expected, the positive alirocumab ..... narrow moat, positive trend rating for Regeneron . While the DME approval was expected ..... estimates, the new indication should allow Eylea sales to re-accelerate in the second

  8. Eylea's 1Q U.S. Sales Soft; Regeneron's Strong Pipeline Progress Continues; Maintaining FVE

    Commentary

    Thu, 8 May 2014

    Regeneron reported first-quarter results that ..... disappointing due to sluggish sales of Eylea in the U.S. However, the company ..... first quarter of 2013. Revenue included Eylea U.S. net product sales of $359 million ..... market share trends. Rest-of-world Eylea sales, as reported by partner Bayer

  9. FDA probes cognitive impact of new cholesterol drugs

    Headlines

    Fri, 7 Mar 2014

    (Reuters) - The Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said...

  10. Regeneron Reports Solid 4Q and Eylea Guidance, Improved Tax Structure; Plan to Raise FVE

    Commentary

    Tue, 11 Feb 2014

    expected tax rate starting in 2017. Regeneron continues to make progress in expanding Eylea ’s label into additional indications ..... and increased R&D spending tied to Regeneron 's expansive clinical and research program, strong Eylea growth helped the firm increase its profit. Regeneron reported adjusted earnings per share

« Prev12345Next »
Content Partners